Cetya Therapeutics Announces Investment

$25,000 investment from Colorado Institute for Drug, Device and Diagnostic Development will advance oncology drug development

Fort Collins, CO, February 1, 2017 – Cetya Therapeutics, Inc. announced the receipt of a $25,000 investment from the Colorado Institute for Drug, Device, and Diagnostic Development (CID4) following a competitive process. CID4 partnered with CSU Ventures to select CSU companies eligible for investment, which were then reviewed by a CID4 panel of outside venture investors and bioscience entrepreneurs to select companies that fit best with CID4’s program. The proceeds will be combined with additional funding to advance the company’s oncology program toward selection of a lead HDAC inhibitor compound and indication.

HDACs (histone deacetylases) are a family of enzymes that are important in regulating expression of many genes, including tumor suppressor genes. It has been demonstrated that inhibition of certain HDACs can increase tumor suppressor gene activity, halting tumor growth. As a drug class, HDAC inhibitors have been demonstrated to be effective in treating lymphomas and certain other cancers. Importantly, thought leaders believe that this class of compounds may have much broader application in treating hemoglobinopathies, such as sickle cell disease, inflammation, neurological disorders and fibrotic diseases. Cetya’s HDAC inhibitor program has focused on highly specific analogs of a HDAC inhibitor called Largazole.
“Largazole and its analogs are among the most potent HDAC inhibitors known, and we are excited to be awarded this funding enabling us to accelerate our preclinical program,” stated Dr. Robert M. Williams, University Distinguished Professor of Chemistry at CSU and a co-founder of Cetya. The largazole analogs represent an opportunity to develop HDAC inhibitors that may mitigate dose-limiting toxicities and serious adverse events that have plagued HDAC inhibitor drug development. Moreover, other HDAC inhibitors in development have shown limited efficacy against solid tumors. Cetya believes its proprietary platform is positioned to overcome theses limitations. Cliff Hendrick, CEO of Cetya, stated, “The ability to evaluate our leading analogs against the biological models for different solid tumors may enable Cetya to pursue a number of oncology clinical indications that have not been possible to date with HDAC inhibitors.”
Cetya has the exclusive worldwide rights to the histone deacetylase (HDAC) inhibitor patent estate developed in the laboratory of Dr. Williams. One of the co-inventors on the IP developed by Dr. Williams is Dr. James E. Bradner, formerly of the Dana Farber Cancer Institute, and now President of Novartis Institutes of Biomedical Research. Dr. Bradner, along with another collaborator of Dr. Williams, Dr. Stuart Schreiber of the Broad Institute, are recognized leaders in understanding the structure and function of HDACs, and in the design of isoform-specific inhibitors of HDACs.

About Cetya Therapeutics
Cetya Therapeutics, Inc. is a Delaware C-Corporation formed in 2012 to develop histone deacetylase inhibitors based on largazole. Some of these analogs incorporate receptor ligands with the potential to target specific cell types or tumors. This is unique for HDAC inhibitors and, together with increased potency and selectivity, differentiates Cetya’s compounds. . More than 30 largazole analogs have been synthesized, some with best-in-class profiles as HDAC inhibitors. Biochemical and cell-based potency, upregulation of fetal hemoglobin expression and in-vivo anti-cancer activity have been demonstrated. Cetya is seeking corporate partners to assist in the advancement of its analog portfolio into clinical studies in a number of different therapeutic indications. For more information on Cetya, please visit our website at

About CID4
Colorado Institute of Drug, Device and Diagnostic Development is a 501(c)(3) nonprofit corporation. CID4’s mission is to improve healthcare outcomes, reduce healthcare costs and promote the growth of the bioscience industry in Colorado by accelerating commercialization of new drugs, medical devices and diagnostics based on discoveries made at Colorado’s research institutions, with a particular focus on cancer therapeutics. For more information on CID4, please visit our website at

About CSU Ventures 
CSU Ventures Inc. is a 501(c)(3) nonprofit corporation that is dedicated to the business of technology transfer and commercialization at Colorado State University, bringing innovations and technologies discovered at CSU into the marketplace for the benefit of society. For more information on CSU Ventures, please visit our website at



Go Back